Tryp Therapeutics Reports on Key Milestones for 2021

San Diego, California–(Newsfile Corp. – April 20, 2021) – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)…

PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial Evaluating Ketamine in the Treatment of Parkinson’s Disease

TORONTO, April 20, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM)…

Cybin Establishes Clinical Advisory Board of Renowned Physicians, Dr. Maurizio Fava, Dr. Lynn Marie Morski and Dr. Anthony Back

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today…

Psychedelic highlights | April 12 – 16

Psychedelic highlights | April 12 – 16 Here is a summary of the news from the…

Core One Labs Negotiates Milestone Acquisition With Akome Biotech Ltd.

VANCOUVER, BC / ACCESSWIRE / April 17, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FRA:LD62)(WKN:A2P8K3) (the “Company”) a…

Ehave Prepares to Launch Ketamine Clinical Trials Using Brain Scientific’s Brain Mapping Technology

MIAMI, April 16, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider…

PharmaTher Provides Update on Psychedelic Product Programs

TORONTO, April 15, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM)…

Medspresso(TM) Partners with CNC Products for Online Listing and CSR Activities

CAPE TOWN, SA / ACCESSWIRE / April 14, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan”…

Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today…

MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company’s Psychedelic Digital Therapeutics Technology Platform

Utilizing Speak Ai’s technology, iSTRYM will provide Ai-driven intelligence to help therapists identify the most efficient…

Psychedelic highlights | April 05 – 09

Psychedelic highlights | April 05 – 09 Here is a summary of the news from the…

MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors

ATMA Was The First Private Sector Service Provider In Canada Conducting Legal Psychedelic-Assisted Therapy For A Palliative Care…